knowledge -WSS

knowledge

author：fashion 2025-09-30 02:09:10 - browse：2

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： What causes an itch? Researchers may have solved the mystery

knowledge

WSS

Patients' immediate access to test results puts radiologists in a bind

Surge of respiratory disease in China has likely explanation

FDA's Woodcock to retire early next year

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Morphosys mixed study results for blood cancer drug

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

focus

knowledge

knowledge

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Patients' immediate access to test results puts radiologists in a bind

How to save PrEP access — and even expand it

AI models in health care face new federal disclosure requirements

Medical leaders decry Supreme Court decision on affirmative action

Gain of function research would be limited under House proposal

Apple is now the first public company to be valued at $3 trillion

FDA approves world's first CRISPR

focus

What causes an itch? Researchers may have solved the mystery

Childhood cancer progress stalls for Black, Hispanic kids: Report

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Childhood cancer progress stalls for Black, Hispanic kids: Report

Congress must reauthorize a committee to support older Americans

Spinal cord stimulation reduces pain in amputees, study finds

explore

knowledge

leisure time

hotspot